Wall Street Zen Upgrades Veru (NASDAQ:VERU) to Hold

Veru (NASDAQ:VERU) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

VERU has been the subject of several other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Veru in a research report on Wednesday, October 8th. Oppenheimer reiterated an “outperform” rating on shares of Veru in a research note on Thursday. Finally, Canaccord Genuity Group began coverage on shares of Veru in a research note on Thursday. They set a “buy” rating and a $25.00 price target for the company. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Veru presently has an average rating of “Moderate Buy” and an average price target of $25.00.

Veru Price Performance

Shares of NASDAQ:VERU opened at $2.32 on Friday. Veru has a 1 year low of $2.11 and a 1 year high of $14.20. The company has a market capitalization of $37.24 million, a PE ratio of -1.05 and a beta of -1.01. The business has a fifty day moving average price of $2.89 and a two-hundred day moving average price of $4.06.

Hedge Funds Weigh In On Veru

A number of institutional investors have recently added to or reduced their stakes in the business. Atria Investments Inc increased its position in shares of Veru by 11.5% in the second quarter. Atria Investments Inc now owns 282,281 shares of the company’s stock worth $164,000 after purchasing an additional 29,025 shares during the last quarter. Allworth Financial LP bought a new stake in Veru during the second quarter valued at approximately $45,000. Sheets Smith Investment Management grew its stake in Veru by 1,341.9% in the 3rd quarter. Sheets Smith Investment Management now owns 322,084 shares of the company’s stock worth $1,224,000 after buying an additional 299,746 shares in the last quarter. Catalyst Funds Management Pty Ltd purchased a new position in Veru in the 2nd quarter worth approximately $36,000. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Veru in the 2nd quarter worth $90,000. 47.16% of the stock is currently owned by institutional investors.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.